If you are searching for Mounjaro 3.75mg, it is important to know that Mounjaro (tirzepatide) is not available as a licensed 3.75mg pen in the UK. The licensed single pen strengths range from 2.5mg to 15mg and are taken once a week as a prescription injection for weight management and type 2 diabetes. Mounjaro has been licensed in the UK since 2023 and should be used alongside a reduced calorie diet and increased physical activity.
For UK adults aged 18 or over exploring private weight loss treatment online, especially if you want the flexibility of buying a single pen rather than committing to a multi pen bundle, this guide explains the available doses, current pricing, eligibility, and what clinical studies have shown. It also covers findings from clinical trials such as SURMOUNT 1, how NICE guidance may apply, and how treatment is prescribed in the UK.
Treatment suitability, including which dose may be appropriate for you, depends on an individual clinical assessment. This guide is for general information only and should not be considered a personal recommendation. A registered prescriber will decide whether treatment is appropriate based on your medical history and health profile.
You will also learn how ordering works with EveryDayMeds, including the online consultation process and home delivery, and why the option to buy a single pen may suit people who want more flexibility when starting treatment.
Mounjaro is not known to be addictive.
What Is Mounjaro (Tirzepatide)? A Guide to Weight Loss Injections
The active ingredient, tirzepatide, is a dual GIP and GLP 1 receptor agonist. If you are wondering how Mounjaro works, it acts on two hormone pathways involved in appetite and blood sugar regulation rather than one. It targets GIP (glucose dependent insulinotropic polypeptide) as well as GLP 1.
Together, these hormones help regulate blood sugar levels, slow stomach emptying, and reduce appetite. Mounjaro may also support weight loss by helping you feel fuller for longer and reducing your appetite. Some people notice changes in their appetite within the first few days, although this varies from person to person.
Mounjaro should be used alongside a reduced calorie diet, increased physical activity, and other healthy lifestyle changes as part of a broader weight management plan. It is not intended to be used as a standalone treatment.
In the UK, Mounjaro is licensed for the treatment of type 2 diabetes and for weight management in eligible adults with obesity or overweight and a weight related health condition. It may also help improve blood sugar control. If Mounjaro is used with certain other diabetes medicines, the risk of low blood sugar may increase. Your prescriber will consider your current medicines and medical history before deciding whether treatment is appropriate.
The Evidence: What SURMOUNT-1 Actually Showed
The main evidence for tirzepatide in weight management comes from the SURMOUNT 1 trial. This was a 72 week, placebo controlled study involving 2,539 adults with obesity, or overweight with at least one weight related health condition, who did not have type 2 diabetes. Across the doses studied, participants achieved average weight reductions of 16.0% with 5mg, 21.4% with 10mg, and 22.5% with 15mg, compared with 2.4% in the placebo group. In the study, 96% of participants receiving the 10mg and 15mg doses achieved at least 5% weight loss, which is a threshold commonly used to indicate a clinically meaningful response.
These results were observed under controlled clinical trial conditions, with structured dietary and lifestyle support, and are not a guarantee of individual results. Results vary from person to person and may depend on factors such as your starting weight, prescribed dose, adherence to treatment, and lifestyle changes. In studies such as SURMOUNT 1, weight loss is measured as a percentage of your starting body weight.
The standard dosing schedule begins with 2.5mg once weekly for four weeks. If appropriate and well tolerated, the dose is usually increased every four weeks. There is no licensed 3.75mg Mounjaro pen available in the UK, and 3.75mg is not a standard maintenance dose. In some situations, a prescriber may recommend an alternative treatment approach based on your individual needs, but there is currently no licensed 3.75mg pen available in the UK.
Is Mounjaro Right for You? NICE Guidance and Eligibility
NICE has published guidance on the use of tirzepatide for managing overweight and obesity (Technology Appraisal TA1026). The guidance sets out the circumstances in which tirzepatide may be recommended, generally based on BMI and the presence of at least one weight related health condition. NHS access is subject to separate commissioning criteria, which may vary between UK nations and local NHS services.
Eligibility criteria and thresholds may change over time. Rather than relying on general guidance, the most reliable way to find out whether treatment may be suitable is through a clinical assessment. At EveryDayMeds, a registered prescriber will assess your medical history, BMI, and overall health to determine whether this weight loss treatment is appropriate for you.
You may be a candidate for assessment if:
- Your BMI is 30 or higher, or 27 or higher with a weight related health condition, such as high blood pressure.
- You have found it difficult to achieve or maintain weight loss through diet and lifestyle changes alone.
- You are willing to use treatment alongside ongoing dietary and lifestyle changes.
Speak to a prescriber first, rather than assuming suitability, if you:
- You are pregnant, trying to conceive, or breastfeeding.
- You have a personal or family history of certain thyroid cancers, including medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- You have certain pancreatic or digestive conditions.
- You are under 18 years of age.
This is not a complete list of situations where Mounjaro may not be suitable. Your clinical assessment will include questions about your medical history, current medicines, and any relevant health conditions. Your prescriber will also explain possible side effects, including uncommon but serious symptoms such as pancreatitis or gallbladder problems that require urgent medical attention if they occur.
Mounjaro Single Pen: Doses, Dosing Schedule and Current UK Pricing
| Dose | Standard Price | First Order Price (code FIRST40) |
|---|---|---|
| 2.5mg | £169.99 | £129.99 |
| 5mg | £199.99 | £159.99 |
| 7.5mg | £249.99 | £209.99 |
| 10mg | £269.99 | £229.99 |
| 12.5mg | £299.99 | £259.99 |
| 15mg | £318.99 | £278.99 |
Each KwikPen contains four weekly maintenance doses, which is approximately one month's treatment when used once a week.
Prices are updated regularly on the website, so the table shown here may not always reflect the latest pricing. The live pricing table on the ordering page should always be used as the most up to date reference.
Returning customers may be eligible for an ongoing discount, which is separate from the first order offer.
Why Buy a Single Pen Rather Than a Bundle?
Single pen ordering may suit a range of situations. For example, it can be a good option if you are starting treatment for the first time and do not want to commit to a multi month supply, if you want to see how you respond to a new dose before ordering more, if you need to bridge between prescriptions, or if you simply prefer to order one month at a time rather than in bulk.
For some people searching for Mounjaro 3.75mg, the search may reflect a desire for more flexibility during dose titration or between prescribed doses. Multi pen bundles, available separately, may offer better value per pen for people on a stable long term dose. However, ordering a single pen can provide greater flexibility if your prescribed dose changes, helping to avoid having unused medication.
In some situations, your prescriber may recommend an alternative dosing approach before you move to your next prescribed dose or instead of taking a full dose. Although a 3.75mg dose may sometimes be used in this way, there is no licensed 3.75mg Mounjaro pen in the UK, and it is not a standard maintenance dose.
What's Included in the Price: Discreet Delivery and More
Every single pen order includes more than just the medicine. It also covers your online clinical assessment and prescription review by a registered prescriber, which are an important part of the treatment process.
The standard clinical assessment is typically completed within 3 working days. If you need a faster review, an express 24 hour assessment option may be available for an additional fee.
If your treatment is approved, your order will be dispatched using temperature controlled, tracked delivery in discreet packaging. A patient information leaflet is included to help you use your prescribed treatment correctly.
How the Ordering Process Works: Security Verification Steps
1. Complete a short online consultation – Fill in a medical questionnaire about your health history, current medicines, weight loss journey, and weight management goals. This usually takes just a few minutes to complete.
2. Clinical review – A GPhC registered prescriber will review your information to determine whether treatment is appropriate for you, taking into account your medical history and other relevant factors.
3. Dispatch and delivery – If your treatment is approved, your order will be dispatched using temperature controlled, tracked delivery. You will also receive guidance on how to store Mounjaro correctly after it arrives.
Quick Takeaways
- All six licensed Mounjaro doses are available as single pens, with prices starting from £169.99 (£129.99 on a first order with the current promotional code). Mounjaro 3.75mg is not a licensed pen strength in the UK.
- Mounjaro is manufactured by Eli Lilly, the company that developed and manufactures the medicine.
- Clinical trial evidence suggests that Mounjaro can support weight loss when used alongside a reduced calorie diet and increased physical activity. In the SURMOUNT 1 trial, participants taking the highest dose achieved an average weight loss of up to 22.5% over 72 weeks, measured as a percentage of their starting body weight. Individual results vary and depend on several factors, including adherence to treatment and lifestyle changes.
- Eligibility is determined through an individual clinical assessment rather than BMI alone. Your prescriber will consider NICE TA1026 guidance, your medical history, and your overall health before deciding whether treatment is appropriate.
- Single pens may suit people who want more flexibility, particularly while their prescribed dose is changing during dose titration. Multi pen bundles may be a better option for people who are established on a stable ongoing dose.
